WASHINGTON — President Trump’s plan to let states and drug wholesalers import medicines from Canada doesn’t apply to every single drug in the same way — and early indications suggest some drug makers have far more to lose than others.
On Wednesday, the Trump administration began a long, regulatory march toward eventually allowing states to import drugs from Canada. While the implementation of that policy is likely to take months, if not years, four states have already passed laws directing their state administrations to submit importation plans to HHS for eventual approval. One state, Florida, has already submitted a plan, and Colorado released an early draft of its plan last month.
FWIW, Nick misleadingly reported the drugs’ **list** prices above. Rebates are substantial for these products, so the list prices do not meaningfully reflect the net cost to a payer. There are also lower list price versions of some products, though payers often favor the high-list/high-rebate versions. See https://www.drugchannels.net/2018/08/2019-express-scripts-formulary.html
Comments are closed.